The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,246.00
Bid: 11,500.00
Ask: 12,470.00
Change: 0.00 (0.00%)
Spread: 970.00 (8.435%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MORNING BID-What's the (dot) plot, Chair Powell?

Wed, 17th Mar 2021 07:56

A look at the day ahead from Dhara Ranasinghe.

It's Federal Reserve day and market focus is on the central
bank's rate-hike projections for 2023 in the so-called "dot
plot."

Some economists expect this to show the Fed now expects one
rate hike for 2023 versus none in December. An unchanged median
dot for 2023 could be interpreted as the Fed pushing back
against higher bond yields and markets' pricing of rate hikes.

The Fed will deliver its statement and economic forecasts at
1800 GMT, followed with a news briefing. Until then, barring
unforeseen events, markets will likely stay calm. Ten-year U.S.
yields are just off 13-month highs, the dollar index
is little changed and equity futures are a touch lower
.

The tone across world stocks is cautious too, with Asian
stocks tracking Wall Street's Tuesday fall and European markets
too set to open softer.

In the euro zone, it's the final day of voting in the Dutch
national election -- the first major general election in the EU
since the pandemic began.

Prime Minister Mark Rutte's VVD Party is expected to secure
a fourth term, but there is a risk markets are not adequately
pricing gains at the ballot for anti-establishment forces.

Some good news for AstraZeneca as Australia's
pharmaceutical regulator said the rollout of the company's
COVID-19 vaccine would continue, despite many European nations
pausing vaccinations to investigate reported side-effects.

The EU regulator will release findings on Thursday.

Elsewhere, Credit Agricole Italia has secured a
green light from European Central Bank supervisors for its
planned takeover bid of third-tier Italian lender Credito
Valtellinese .
Key developments that should provide more direction to markets
on Wednesday:

- Fed monetary policy decision and news conference.

- German, UK German new car registration data.

- US housing starts data due.

- Corporates: BMW said it expects a significant year-on-year
increase in pretax profit; Raiffeisen Bank aims to distribute
20%-50% of consolidated net profits; retail investment platform
Hargreaves Lansdown 2021 profit to beat expectations.

- Italy's biggest insurer Generali is studying an
acquisition in Russia worth nearly 2 billion euros ($2.4
billion), according to a media report.

(Reporting by Dhara Ranasinghe; Editing by Sujata Rao)

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.